search
Back to results

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

Primary Purpose

HIV Infections

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PrEP
Sponsored by
Yale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV Infections focused on measuring HIV pre-exposure prophylaxis, criminal justice, women, risk networks

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Index participants reside in, or planning to reside in New Haven or Hartford, Connecticut,.
  • Criminal justice-involved (anticipate release or have been released from prison or jail within 6 months, and/or are under or anticipating transfer to correctional community supervision (i.e. probation or parole)).
  • Self-reported HIV negative.

Eligible and enrolled women will then recruit risk network members through respondent driven sampling, using vouchers.

Risk network members must:

  • have a unique and valid referral coupon (from Index participant).
  • Reside or planning to reside in New Haven or Hartford, Connecticut.
  • Self-reported HIV negative
  • 18 years of age or older

Exclusion Criteria:

  • They are unable or unwilling to provide informed consent.
  • Are threatening to staff.

Sites / Locations

  • Yale Clinical and Community Research, 270 Congress Ave

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PrEP

Arm Description

For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.

Outcomes

Primary Outcome Measures

% PrEP uptake
# starting PrEP/ # enrolled subjects
% eligible PrEP uptake
# starting PrEP/ # eligible subjects

Secondary Outcome Measures

Mean % PrEP adherence
# PrEP pills taken/# PrEP pills prescribed per month
Mean TDF level
TDF level by dried blood spot testing
HIV incidence
New HIV+ by 4th generation HIV Ag/Ab testing

Full Information

First Posted
September 20, 2017
Last Updated
July 27, 2021
Sponsor
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT03293290
Brief Title
Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks
Official Title
Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
December 11, 2017 (Actual)
Primary Completion Date
May 15, 2020 (Actual)
Study Completion Date
May 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study has two components. The first component is designed to assess and compare the awareness, attitudes and clinical eligibility of Pre-exposure Prophylaxis (PrEP) in criminal justice (CJ) involved women. The second component is designed to evaluate the acceptability and feasibility of strategically delivering PrEP to CJ involved women and their risk network members.
Detailed Description
Risk networks can be leveraged to maximally disseminate effective interventions to women, including PrEP, and thereby potentially avert some of the 50,000 annual incident HIV infections in the U.S. Few studies to date have capitalized on risk networks as a way to identify and engage high-risk individuals, like CJ-involved women, who could markedly benefit from PrEP. This study advances the field by: 1) Using an innovative network-based framework (a non-traditional model of care delivery) to engage a high risk population in PrEP dissemination as HIV prevention; 2) Incorporating a syndemic approach to PrEP that addresses HIV prevention in the context of substance use, psychiatric comorbidities, IPV, and stigma; and 3) Recruiting, enrolling, and retaining high risk networks of CJ-involved women who are difficult to reach by other means. In doing so, this proposal addresses key funding priorities of the Gilead Investigator Sponsored Research program, which includes research on PrEP implementation targeted to high risk populations and delivered in non-traditional clinical settings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
HIV pre-exposure prophylaxis, criminal justice, women, risk networks

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
105 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PrEP
Arm Type
Experimental
Arm Description
For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.
Intervention Type
Drug
Intervention Name(s)
PrEP
Other Intervention Name(s)
TDF/FTC
Intervention Description
Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
Primary Outcome Measure Information:
Title
% PrEP uptake
Description
# starting PrEP/ # enrolled subjects
Time Frame
Month 1
Title
% eligible PrEP uptake
Description
# starting PrEP/ # eligible subjects
Time Frame
Month 1
Secondary Outcome Measure Information:
Title
Mean % PrEP adherence
Description
# PrEP pills taken/# PrEP pills prescribed per month
Time Frame
12 months
Title
Mean TDF level
Description
TDF level by dried blood spot testing
Time Frame
12 months
Title
HIV incidence
Description
New HIV+ by 4th generation HIV Ag/Ab testing
Time Frame
12 months

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Cis- or trans- female participants are eligible.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Index participants reside in, or planning to reside in New Haven or Hartford, Connecticut,. Criminal justice-involved (anticipate release or have been released from prison or jail within 6 months, and/or are under or anticipating transfer to correctional community supervision (i.e. probation or parole)). Self-reported HIV negative. Eligible and enrolled women will then recruit risk network members through respondent driven sampling, using vouchers. Risk network members must: have a unique and valid referral coupon (from Index participant). Reside or planning to reside in New Haven or Hartford, Connecticut. Self-reported HIV negative 18 years of age or older Exclusion Criteria: They are unable or unwilling to provide informed consent. Are threatening to staff.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jaimie Meyer, MD, MS, FACP
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale Clinical and Community Research, 270 Congress Ave
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
35672552
Citation
Meyer JP, Price CR, Ye Y, Qin Y, Tracey D, Demidont AC, Melbourne K, Altice FL. A PrEP Demonstration Project Using eHealth and Community Outreach to Justice-Involved Cisgender Women and Their Risk Networks. AIDS Behav. 2022 Dec;26(12):3807-3817. doi: 10.1007/s10461-022-03709-2. Epub 2022 Jun 7.
Results Reference
derived

Learn more about this trial

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

We'll reach out to this number within 24 hrs